Association between FAS polymorphism and prostate cancer development

• Tipo: Artigo em Revista Científica Internacional
• Data: 2008

Autores

Lima, L (Autor) Outra; Morais, A (Autor) Outra; Lobo, F (Autor) Outra; Calais da Silva, FM (Autor) Outra; Calais da Silva, FE (Autor) Outra; Medeiros, R (Autor) ICBAS

Revista

Título: Prostate Cancer and Prostatic Diseases

Vol. 11

Páginas: 94-98

ISSN: 1365-7852

Editora: Springer Nature

Indexação

ISI Web of Knowledge - 25 Citações

Scopus - 29 Citações

Classificação Científica

FOS: Ciências médicas e da saúde > Medicina clínica

Outras Informações

ID Authenticus: P-004-1C4

DOI: 10.1038/sj.pcan.4501002

Abstract (EN): The role of FAS polymorphisms in prostate cancer has not been studied. Using the PCR-based restriction fragment-length polymorphism methodology, we evaluated FAS gene locus -670 genotypes in DNA from 904 men: 657 prostate cancer patients and 247 healthy controls. We found that carriers of AG or GG genotypes have a statistically significant protection ( odds ratio ( OR)=0.30; confidence interval ( CI): 0.20-0.44 and OR 0.22; CI: 0.12-0.74, respectively) for disease with extra-capsular invasion. Taken together, a 72% protection was found for G allele carriers ( OR=0.28; CI: 0.19-0.41). Fas exist as membrane-bound and soluble forms and with opposite roles. They derive from the same gene by alternative splicing. Membrane Fas receptors trigger apoptosis whereas, on the other hand, soluble Fas ( sFas) bind to Fas ligand antagonizing Fas-Fas ligand apoptotic pathway. Our results suggest that G allele may reduce sFas levels preventing the apoptotic inhibition caused by the soluble form.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 5